PsychoGenics’ Post

We're thrilled to announce the expansion of our assay menu with the introduction of Simoa® ALZpath p-Tau 217 Advantage PLUS. Research shows that p-Tau 217 levels are significantly elevated in patients with Alzheimer's disease, even in the early stages, making it a valuable marker. Designed to synergize with the HD-X™ Automated Analyzer, the new p-Tau 217 brings improved lot-to-lot consistency, making it ideal for longitudinal studies and large-scale research. Learn how researchers are leveraging the precision of Advantage Plus to advance their research ➡ https://bit.ly/3wVsogb #Alzheimers #ALZpath #Biomarkers

Fosgonimeton demonstrated encouraging pro-cognitive effects in clinical trials, supporting its continued development for the treatment of #Parkinsons Disease.     On the heels of #ADPD2024, Andrea Lobo, Ph.D. of Parkinson's News Today highlights our SHAPE Phase 2 #fosgonimeton results, its mechanism of action, and supporting preclinical data in her recent article.     Read it here: https://bit.ly/4awTtoC

Excellent confirmation of the efficacy of Cognivue in detecting cognitive difficulties!

“We're very confident that there is potential in this mechanism and excited to see if it translates in the clinic."    On the ground at #AAN24, our CSO Kevin Church, Ph.D. interviewed with NeurologyLive to discuss how our HGF compounds target neurotrophic deficits in neurodegenerative diseases such as AD, PD, and ALS.    Watch the full interview and learn more about our upcoming clinical milestones in #AD and #ALS: https://bit.ly/49YlSCI  

🌟 Exciting news from our Bio-Hermes study partners Cognivue, Inc.! Their Cognivue Clarity® has shown remarkable ability to discriminate healthy controls from those with Mild Cognitive Impairment and Alzheimer’s disease using some of the Bio-Hermes biomarker data. Not only that, but it also strongly correlates with AD biomarkers and may have impressive psychometric properties. This might be a game-changer in the field of cognitive assessment! #BioHermes #alzheimersdisease 🧠🔬https://bit.ly/3w3MkNz

Neurodegenerative disorders are for some people an everyday living nightmare - Either as a patient or as a close relative. The below article is a step in the right direction to expand the knowledge we have on ALS by looking into the genes. I hope that the near future will bring even more knowledge and awareness on the neurodegenerative disorders! #ALS #neurodegenerativedisorders #clinicaltrials

Technology Tuesday - Week 3 The Michael J. Fox Foundation's breakthrough in Parkinson's disease research introduces the "alpha-synuclein seeding amplification assay" (SAA), a test capable of detecting early signs of the disease with 90% specificity. This groundbreaking procedure identifies misfolded alpha-synuclein in spinal fluid, a key indicator of Parkinson's. The SAA test, integrated into drug trials, objectively identifies individuals with targeted biology, enhancing drug development accuracy. Remarkably, the SAA breakthrough originated from a large-scale observational study that utilized a scratch-and-sniff test, revealing a strong link between poor smell and Parkinson's, paving the way for a simple and accessible screening mechanism in 2024. #ParkinsonsResearch #MedicalBreakthrough #NeurologicalHealth #HealthInnovation #BiomedicalScience #AlphaSynuclein #SAAtest #EarlyDetection #HealthcareAdvancements #MJFFoundation #NeurodegenerativeDiseases #InnovativeHealthcare #HealthTech #MedicalDiscovery #ResearchMilestones #1872Consulting #TechTuesday #TechnologyTuesday https://lnkd.in/g2Nq58Nm

Our new Article entitled "Ferroptosis in the Pathogenesis of Alzheimer’s Disease: The New Evidence for Validation of FAB Model" has just been published with Springer Nature Group in Neurochemical Journal and is ready to be viewed, downloaded, and cited. 💡 Here we: ❗ Focused on the mechanisms of ferroptosis in the pathogenesis of Alzheimer’s Disease. ❗ Overviewed the available in vivo and in vitro models used to study ferroptosis in Alzheimer’s Disease. ❗Described in detail the ferrous amyloid buthionine (FAB) model. ❗Discussed the ferroptosis as possible theraputic target for Alzheimer’s Disease. This review is result of sum work done by #YSMU #Cobrain #Neurolab team members - Hasmik Harutyunyan, Arpine Khamperyan, Gohar Karapetyan & Katarine Fereshetyan. #hesc Take a look at our article!

NeuroRestore & Alzstatin – with focus on Alzheimer’s disease NeuroRestore is a platform of symptomatic drug candidates for diseases where learning and memory ability is impaired, such as Alzheimer’s. NeuroRestore stimulates important signal pathways in the brain, which among other things leads to improved learning and memory abilities. In preclinical studies with #NeuroRestore, we have been able to demonstrate that our drug compounds not only boost communication between nerve cells but also improve learning and memory abilities. The drug candidates in NeuroRestore stimulate signaling of neurotrophins, the most well-known of which is Nerve Growth Factor (NGF) and Brain Derived Neurotrophic Factor (BDNF). These neurotrophins are important for maintaining nerve cell function and communication, which are impaired with cognitive disorders. BDNF plays an important role for nerve cell function and communication in the areas of the brain that are essential for our learning and memory abilities, such as the hippocampus, located in the temporal lobe. Our disease-modifying research platform #Alzstatin consists of gamma-secretase modulators (GSMs). GSMs reduces the production of toxic amyloid beta protein (Aβ42) in the brain. Aβ42 plays a key pathogenic role in #Alzheimer’s disease and begins to accumulate in the brain years before clear symptoms of Alzheimer’s start to develop. Read and learn about our platform: https://lnkd.in/d8PfuGj9 Read and learn about our platform: https://lnkd.in/dS8XGTGq #alzecure #Neurorestore #Alzstatin #redeye #alzheimerfonden #avanza #nordnet #edisongroup #seb #swedbank #nordea #aktiespararna #privataaffarer #vatorsecurities #finwire #erikpenserbank #alzehimersdisease #cognitivedisorders #gammasecretase #Aβ42 #amyloidbeta

🧠 Exciting New Research on Psilocybin for Huntington's Disease Treatment! 🌱 The URNCST Journal is excited to share a new research protocol exploring the potential of psilocybin to treat Huntington's Disease (HD), a devastating neurodegenerative disorder that causes progressive neuron death in the brain. In this publication, the authors propose using psilocybin, known for its neuroprotective, neurotrophic, and neuroplastic properties, to reduce neuron loss and improve motor functions in zQ175 knock-in (KI) mice, which model HD. By analyzing brain samples and motor control through behavioral tests, they aim to uncover whether psilocybin can slow HD progression. 📈 Expected results: - Decreased neuronal death 🧠 - Increased synaptic density 🌿 - Improved motor control 🏃 If successful, this study could pave the way for future clinical trials and potentially improve the quality of life for those affected by Huntington's Disease. Read the full article here: https://lnkd.in/g6jsTCNe #URNCST #ResearchProtocol #HuntingtonsDisease #psilocybin #SynapticDensity #5HT2AReceptor